Latest Ratios: P/E Ratio -0.6x · EV/EBITDA N/A · ROE -222.8%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $18M | $33M | — | — | — | — | — |
| Enterprise Value | $-2614633 | $13M | — | — | — | — | — |
| P/E Ratio → | -0.59 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 0.71 | 1.60 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 88.6% | 69.3% | 82.1% | 93.3% | — |
| Operating Margin | — | — | -781.6% | -579.4% | -209.1% | -386.8% | 4.0% |
| Net Profit Margin | — | — | -993.0% | -565.2% | -204.2% | -384.1% | 6.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -222.8% | -222.8% | — | — | -93.7% | -37.1% | 3.4% |
| ROA | -48.0% | -48.0% | -200.1% | -328.8% | -58.5% | -34.1% | 3.1% |
| ROIC | -1696.5% | -1696.5% | -2143.2% | — | -85.5% | -30.3% | 1.8% |
| ROCE | -87.9% | -87.9% | -175.5% | -376.5% | -64.8% | -37.0% | 2.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | — | — | — | 0.02 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | 0.82 |
| Net Debt / Equity | — | -0.98 | — | — | — | -0.04 | -0.11 |
| Net Debt / EBITDA | — | — | — | — | — | — | -4.13 |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -7.41 | — | -28491.33 | — | — |
Net cash position: cash ($21M) exceeds total debt ($201000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.86 | 2.86 | 11.03 | 7.97 | 10.31 | 9.84 | 10.55 |
| Quick Ratio | 2.86 | 2.86 | 10.81 | 7.97 | 10.31 | 9.69 | 10.55 |
| Cash Ratio | 2.79 | 2.79 | 9.54 | 6.99 | 10.23 | 9.48 | 9.79 |
| Asset Turnover | — | — | 0.16 | 0.78 | 0.93 | 0.09 | 0.50 |
| Inventory Turnover | — | — | 0.90 | — | — | 0.60 | — |
| Days Sales Outstanding | — | — | 229.88 | 69.93 | 38.82 | 18.26 | 5.58 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $8M | $2M | $9M | $9M | $1M | $1M |
Clinical trial funding shortfall
Based on reported figures, Tvardi trades at a price-to-book ratio of 0.69, which suggests that the market is heavily discounting the company's intellectual property and clinical assets compared to the broader biotechnology sector, likely due to the binary nature of its upcoming Phase 2 data readouts.
The current P/B multiple indicates that investors are pricing the company below its accounting book value, a common occurrence for pre-revenue firms where the market questions the long-term viability of the pipeline. This valuation level implies that the market is not assigning significant premium to the STAT3 inhibition platform, potentially overlooking the therapeutic potential in fibrosis.
As reported in financial statements, Tvardi's ROIC has remained deeply negative, reaching -160.5% in 2025Q4, which highlights the company's current inability to generate returns on invested capital while it remains in the high-cost, pre-revenue phase of its clinical development cycle.
The persistent decay in ROIC is a direct consequence of heavy R&D spending without corresponding revenue generation. Investors should monitor whether the company can improve these returns through potential licensing deals or milestone payments, as the current trend suggests significant capital destruction inherent to the drug development process.
According to recent SEC filings, Tvardi maintains a current ratio of 2.86 as of 2025Q4, which appears adequate on the surface but masks the reality that the company's cash reserves are rapidly depleting to fund ongoing Phase 2 clinical trials for TTI-101.
While the current ratio suggests sufficient short-term liquidity to cover immediate liabilities, the lack of revenue means this buffer is strictly finite. The company's reliance on cash-on-hand to sustain operations warrants further investigation into the timing of potential capital raises, as the current burn rate may exhaust these resources within the next year.
The most commonly misapplied ratio for Tvardi is the P/E ratio, which, as reported in financial statements, is currently negative and fundamentally obscures the company's true value by focusing on accounting losses rather than the clinical progress of its STAT3-targeting pipeline.
Using P/E to evaluate a pre-revenue clinical-stage firm is misleading because it treats R&D expenses as operational failures rather than investments in future intellectual property. Analysts should instead focus on cash runway and the probability-adjusted net present value of the clinical pipeline to better assess the company's fundamental worth.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TVRD stock.
Tvardi Therapeutics, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
Tvardi Therapeutics, Inc.'s return on equity (ROE) is -222.8%. The historical average is -87.5%.
Based on historical data, Tvardi Therapeutics, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.